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We report the case of a 51-year-old gentleman presenting with obstructive and irritative urinary
symptoms, found to have a large prostate mass on imaging. A radical prostatectomy was performed and
pathological diagnosis revealed a 12 cm mammary-type myoﬁbroblastoma replacing the entire prostate.
Mammary-type myoﬁbroblastoma is a rare lesion outside of the breast, and is considered benign. This is
the ﬁrst reported case of a mammary-type myoﬁbroblastoma occurring in the prostate.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Mammary-type myoﬁbroblastoma is a rare, benign, neoplasm
that is histologically and immunophenotypically identical to
mammary myoﬁbroblastoma, a benign breast tumor. Mammary-
type myoﬁbroblastoma was ﬁrst described in 2001, in a series of 9
cases with tumors arising at extra-mammary sites.1 To date, there
are only approximately 160 cases of extra-mammary myoﬁbro-
blastoma reported in the literature.2 None of these cases arose in
the prostate.
We present a case of a large mammary-type myoﬁbroblastoma
arising in the prostate presenting with urinary obstruction.Case presentation
A 51-year-old man presented with bothersome lower urinary
tract symptoms that were both obstructive and irritative in na-
ture. Four months prior to presentation, he had an episode of
urinary retention and presented to an outside hospital. Placement
of a Foley catheter in the emergency room was unsuccessful, and
eventually a Foley was placed over a guide wire at the time of
cystoscopy in the operating room. MRI of the pelvis revealed an
enormous lobulated mass involving the prostate gland measuring
12.7  7.9  6.7 cm (Fig. 1). The mass also involved the root of the
penis and elevated the bladder base. Prostate needle biopsy wasS was responsible for editing
.J. Cohen).
Inc. This is an open access article uconsistent with a diagnosis of mammary-type myoﬁbroblastoma.
The patient underwent a radical retropubic prostatectomy with
an en bloc resection of this large prostatic mass. Our orthopedic
colleagues resected the anterior pubic arch, which facilitated
surgical exposure of the root of the penis and urethra. The urethra
was divided distal to the membranous urethra to ensure negative
surgical margins. The distance between the bladder neck and
urethra was too wide to do an anastomosis, therefore the dome of
the bladder was released from its peritoneal attachments and
rotated forward. This maneuver permitted a tension anastomosis
between bladder dome and urethra. The patient was made aware
of the fact preoperatively that an artiﬁcial urinary sphincter
would likely be required to manage post prostatectomy
incontinence.
Gross examination revealed a 12.0 cm, multi-nodular, white
mass distorting the normal prostate (Fig. 2). Histology revealed
sheets of myoﬁbroblastic spindle cells with poorly deﬁned borders
(Fig. 3A). The neoplastic cells were immunoreactive for CD 34
(Fig. 3B) and desmin (Fig. 3C). Given the morphology and immu-
noreactivity, a diagnosis of mammary-type myoﬁbroblastoma
involving the prostate was made. The seminal vesicles and surgical
resection margins were negative for tumor. There was no evidence
of prostatic adenocarcinoma. The post operative course has been
uncomplicated so far.
Discussion
Myoﬁbroblastoma was ﬁrst described in 1987 as a benign, soft
tissue tumor of the breast.3 The tumor is characteristically well-
circumscribed, composed of uniform spindle cells haphazardly ar-
ranged in fascicles with pushing borders, separated by bands ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. MRI demonstrating a 12.7 cm mass (white arrow) involving the prostate.
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removal is curative.3 On immunohistochemistry, these lesions are
characteristically positive for CD 34 and desmin, with variable
staining for smooth muscle actin.4
An extra-mammary location of a myoﬁbroblastoma is rare, and
was ﬁrst reported in 2001.1 Recently, the largest case series to date
was published characterizing 143 cases of mammary-typeFigure 2. Serially sectioned prostatectomy specimmyoﬁbroblastoma. Demographically, themean age of diagnosis was
54 years-old with a male predominance (66%). The most common
anatomic site of these tumors was the inguinal region, though there
was a wide anatomic distribution. Mammary-type myoﬁbro-
blastoma is thought to be a benign lesion that is curable by resec-
tion. Out of the cohort of 143 cases, 1 of the cases was reportedly a
recurrence 20 years after initial excision. Even in the 8 cases with
positive surgical margins, there has not been evidence of recur-
rence.2 This is the ﬁrst reported case of a mammary-type myoﬁ-
broblastoma involving the prostate.
Included in the differential diagnosis for mammary-type
myoﬁbroblastoma are both benign and malignant tumors.
While mammary-type myoﬁbroblastoma is most confused with
spindle cell lipoma (SCL), a benign entity, the differential also
includes other benign neoplasms, such as cellular angioﬁbroma
and angiomyoﬁbroblastoma, and malignant lesions, such as
spindle cell liposarcoma and low-grade malignant peripheral
nerve sheath tumor.1 Differentiating mammary-type myoﬁbro-
blastoma from SCL is often difﬁcult. Both lesions are benign,
spindle cell neoplasms that show immunoreactivity with CD34.
Subtle histological differences between the lesions do exist, as
mammary-type myoﬁbroblastomas have less fat than SCLs and
contain a more prominent, hyalinized stroma. In addition,
mammary-type myoﬁbroblastomas show desmin positivity on
immunohistochemistry, while SCLs do not.1 The sensitivity of
CD34 and desmin for detecting mammary-type myoﬁbro-
blastoma is 89% and 91%, respectively.2 Mammary-type myoﬁ-
broblastomas and SCLs also show identical cytogenetic changes,
with partial loss of the 13q14 chromosomal region.5 Genetically,
this alteration results in loss of Rb expression.2
Given the benign behavior of mammary-type myoﬁbro-
blastoma, it is imperative to properly distinguish it from
potential malignant counterparts. Careful gross examination of
the resection specimen is important to exclude malignanten with a 12 cm mass replacing the prostate.
Figure 3. H & E stain (20) of a mammary-type myoﬁbroblastoma (A); cells of interest stain positive for CD34 (B) and desmin (C).
A.J. Cohen, G.S. Steele / Urology Case Reports 8 (2016) 44e4646features, such as areas of hemorrhage and necrosis. In addition,
careful histological and immunohistochemical analysis, in
consultation with an expert in soft tissue pathology, is essential
to rule out malignancy.
Conclusion
Our case is the ﬁrst reported occurrence of a mammary-type
myoﬁbroblastoma arising in the prostate. Mammary-type myoﬁ-
broblastoma is a rare lesion outside of the breast and has proven to
be benign, with no reports of metastasis and only a single reported
episode of recurrence 20 years after initial excision. It is essential to
distinguish this benign entity from similar malignant lesions to
avoid improper treatment and prognosis.
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